Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

GT Biopharma (GTBP) EBIT Margin (2018 - 2021)

GT Biopharma (GTBP) has disclosed EBIT Margin for 7 consecutive years, with 82627.27% as the latest value for Q4 2021.

  • On a quarterly basis, EBIT Margin changed N/A to 82627.27% in Q4 2021 year-over-year; TTM through Dec 2021 was 261431.82%, a N/A change, with the full-year FY2025 number at 9781.1%, changed N/A from a year prior.
  • EBIT Margin was 82627.27% for Q4 2021 at GT Biopharma, up from 7264.1% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 82627.27% in Q4 2021 to a low of 475.78% in Q2 2019.
  • A 3-year average of 27815.74% and a median of 14079.96% in 2018 define the central range for EBIT Margin.